<DOC>
	<DOCNO>NCT02702141</DOCNO>
	<brief_summary>The study examine safety profile SGN-CD19B administer single agent . The main purpose study estimate high dose cause unacceptable side effect SGN-CD19B patient relapse refractory aggressive B-cell non-Hodgkin lymphoma ( NHL ) subtypes diffuse large B-cell lymphoma ( DLBCL ) Grade 3 follicular lymphoma ( FL3 ) . Additionally , pharmacokinetic profile antitumor activity SGN-CD19B assess .</brief_summary>
	<brief_title>A Safety Study SGN-CD19B Patients With B-cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>SGN-CD19B give patient increase dos every 28 day ( alternative dosing schedule every 42 day ) . Individual expansion cohort approximately 20 patient open dose level select Safety Monitoring Committee base aggregate know safety activity data define safety antitumor activity refractory relapse disease subgroup .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Relapsed , refractory , progressive disease follow least 2 prior systemic therapy Measurable disease Eastern Cooperative Oncology Group status 0 1 Adequate baseline renal hepatic function Prior treatment CD19 direct agent unless CD19 expression confirm completion CD19directed treatment Known HIV , active hepatitis B active hepatitis C infection Prior allogeneic stem cell transplant Inadequate lung function Anticancer treatment within 4 week study drug 2 week patient experience disease progression prior treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non-hodgkin lymphoma</keyword>
	<keyword>Antibody-drug conjugate</keyword>
	<keyword>CD19</keyword>
	<keyword>Diffuse large B-cell lymphoma</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Grade 3 follicular lymphoma</keyword>
</DOC>